To propose a regulatory framework for peptide compounds that balances access and safety.
Approach:
Current Landscape: Peptide use is increasing among Americans, often sourced from unregulated markets without medical supervision.
Regulatory Opportunity: The FDA can create a structured, clinician-guided framework for peptide access rather than opting for unrestricted access or a total crackdown.
Proposed Framework: Selected peptides should be available through licensed pharmacies under strict oversight, with clinician involvement in patient evaluation and monitoring.
Key Findings:
Some peptides are FDA-approved and transformative, while others lack regulatory scrutiny and safety evidence.
Prohibition-style approaches do not eliminate demand and may push consumers to riskier markets.
A structured oversight system can improve safety, generate real-world evidence, and respect patient autonomy.
Interpretation:
The FDA has the opportunity to regulate peptide use effectively while ensuring patient safety and gathering necessary evidence.
Limitations:
The proposed system does not replace full FDA approval pathways.
Compounded medications would not equal rigorously tested drugs.
Conclusion:
A structured, clinician-guided approach can protect patients and gather evidence for the future of peptide use.
